Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 101 - 150 av 380 resultater
Tid
Selskap
Tittel
Sektor
Kategori
08 Feb 2024
06:58 CET
IPSEN
Après de solides résultats pour l’année 2023, Ipsen anticipe quatre lancements commerciaux en 2024.
20103015 Pharmaceuticals
Commercial results
08 Feb 2024
06:58 CET
IPSEN
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
20103015 Pharmaceuticals
Commercial results
06 Feb 2024
18:00 CET
IPSEN
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
06 Feb 2024
18:00 CET
IPSEN
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Share history
22 Jan 2024
23:00 CET
IPSEN
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
20103015 Pharmaceuticals
Products and services
22 Jan 2024
23:00 CET
IPSEN
Ipsen présente les dernières données d'un essai de Phase III évaluant Cabometyx® en association avec une immunothérapie à l'occasion de l'édition 2024 de l'ASCO sur les cancers génito-urinaires
20103015 Pharmaceuticals
Products and services
08 Jan 2024
18:00 CET
IPSEN
Ipsen – Half year statement – 2023 12 31
20103015 Pharmaceuticals
Other subject
08 Jan 2024
18:00 CET
IPSEN
Ipsen – Bilan semestriel – 2023 12 31
20103015 Pharmaceuticals
Other subject
05 Jan 2024
18:00 CET
IPSEN
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Share history
05 Jan 2024
18:00 CET
IPSEN
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
07 Dec 2023
18:49 CET
IPSEN
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Share history
07 Dec 2023
18:49 CET
IPSEN
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
07 Dec 2023
07:00 CET
IPSEN
Journée Investisseurs 2023 - Ipsen présente sa prochaine phase de croissance et de transformation et ses nouvelles perspectives à moyen terme
20103015 Pharmaceuticals
Other subject
07 Dec 2023
07:00 CET
IPSEN
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
20103015 Pharmaceuticals
Products and services
07 Dec 2023
07:00 CET
IPSEN
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
20103015 Pharmaceuticals
Other subject
07 Dec 2023
07:00 CET
IPSEN
Ipsen confirme la décision de la FDA d'accorder un examen prioritaire pour le dépôt du dossier de demande d'autorisation d'elafibranor dans le traitement de la cholangite biliaire primitive, une maladie cholestatique rare du foie
20103015 Pharmaceuticals
Products and services
14 Nov 2023
18:00 CET
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 45 - 2023
20103015 Pharmaceuticals
Share history
14 Nov 2023
18:00 CET
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2023
20103015 Pharmaceuticals
Share history
13 Nov 2023
22:30 CET
IPSEN
Les résultats de l’essai pivot de Phase III ELATIVE® d’Ipsen avec élafibranor dans la PBC présentés comme données de dernière minute au congrès de l’AASLD et publiés dans le New England Journal of Medicine
20103015 Pharmaceuticals
Products and services
13 Nov 2023
22:30 CET
IPSEN
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
20103015 Pharmaceuticals
Products and services
07 Nov 2023
18:00 CET
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2023
20103015 Pharmaceuticals
Share history
07 Nov 2023
18:00 CET
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 44 - 2023
20103015 Pharmaceuticals
Share history
06 Nov 2023
18:00 CET
IPSEN
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Share history
06 Nov 2023
18:00 CET
IPSEN
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
31 Oct 2023
18:00 CET
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2023
20103015 Pharmaceuticals
Share history
31 Oct 2023
18:00 CET
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 43 - 2023
20103015 Pharmaceuticals
Share history
26 Oct 2023
07:00 CEST
IPSEN
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
20103015 Pharmaceuticals
Commercial results
26 Oct 2023
07:00 CEST
IPSEN
Ipsen enregistre une solide croissance de ses ventes au cours des neuf premiers mois de 2023 et confirme ses objectifs pour l’exercice en cours
20103015 Pharmaceuticals
Commercial results
24 Oct 2023
18:00 CEST
IPSEN
IPSEN - Buy-back program - Art 5 of MAR - Week 42 - 2023
20103015 Pharmaceuticals
Share history
24 Oct 2023
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 42 - 2023
20103015 Pharmaceuticals
Share history
23 Oct 2023
07:00 CEST
IPSEN
Ipsen fait le point sur la demande d’Autorisation de Mise sur le Marché européen d’odévixibat pour traiter le syndrome d'Alagille
20103015 Pharmaceuticals
Products and services
23 Oct 2023
07:00 CEST
IPSEN
Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
20103015 Pharmaceuticals
Products and services
17 Oct 2023
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 41 - 2023
20103015 Pharmaceuticals
Share history
17 Oct 2023
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 41 - 2023
20103015 Pharmaceuticals
Share history
10 Oct 2023
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 40 - 2023
20103015 Pharmaceuticals
Share history
10 Oct 2023
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2023
20103015 Pharmaceuticals
Share history
06 Oct 2023
18:00 CEST
IPSEN
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Share history
06 Oct 2023
18:00 CEST
IPSEN
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
03 Oct 2023
18:00 CEST
IPSEN
Ipsen updates on QM-1114 regulatory process
20103015 Pharmaceuticals
Products and services
03 Oct 2023
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2023
20103015 Pharmaceuticals
Share history
03 Oct 2023
18:00 CEST
IPSEN
Ipsen fait le point sur la procédure réglementaire de la toxine QM-1114
20103015 Pharmaceuticals
Products and services
03 Oct 2023
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 39 - 2023
20103015 Pharmaceuticals
Share history
26 Sep 2023
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2023
20103015 Pharmaceuticals
Share history
26 Sep 2023
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 38 - 2023
20103015 Pharmaceuticals
Share history
19 Sep 2023
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2023
20103015 Pharmaceuticals
Share history
19 Sep 2023
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 37 - 2023
20103015 Pharmaceuticals
Share history
12 Sep 2023
18:00 CEST
IPSEN
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 36 - 2023
20103015 Pharmaceuticals
Share history
12 Sep 2023
18:00 CEST
IPSEN
IPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 2023
20103015 Pharmaceuticals
Share history
08 Sep 2023
18:00 CEST
IPSEN
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
20103015 Pharmaceuticals
Share history
08 Sep 2023
18:00 CEST
IPSEN
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
20103015 Pharmaceuticals
Share history
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva